Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality. Fibroblast growth factor 21 (FGF-21) and monocyte chemoattractant protein 1 (MCP-1) are associated with cardiovascular disease and systemic inflammation. We investigated FGF-21 and MCP-1 in relations to cardiac function, inflammation, and wasting in patients with heart failure with reduced ejection fraction (HFrEF) and cardiac cachexia.

METHODS AND RESULTS: Plasma FGF-21 and MCP-1 were measured in a cross-sectional study among the three study groups: 19 patients with HFrEF with cardiac cachexia, 19 patients with HFrEF without cachexia, and 19 patients with ischaemic heart disease and preserved ejection fraction. Patients with HFrEF and cardiac cachexia displayed higher FGF-21 levels median (inter quantile range) 381 (232-577) pg/mL than patients with HFrEF without cachexia 224 (179-309) pg/mL and ischaemic heart disease patients 221 (156-308) pg/mL (P = 0.0496). No difference in MCP-1 levels were found among the groups (P = 0.345). In a multivariable regression analysis, FGF-21 (logarithm 2) was independently associated with interleukin 6 (logarithm 2) (P = 0.015) and lower muscle mass (P = 0.043), while no relation with N-terminal pro-hormone brain natriuretic peptide was observed.

CONCLUSIONS: Fibroblast growth factor 21 (FGF-21) levels were elevated in patients with HFrEF and cardiac cachexia, which could be mediated by increased inflammation and muscle wasting rather than impaired cardiac function.

TidsskriftESC Heart Failure
Udgave nummer5
Sider (fra-til)983-991
Antal sider9
StatusUdgivet - okt. 2019

Bibliografisk note

© 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

ID: 59042118